[go: up one dir, main page]

CA2307953A1 - Therapie genique pour la stimulation de l'angiogenese - Google Patents

Therapie genique pour la stimulation de l'angiogenese Download PDF

Info

Publication number
CA2307953A1
CA2307953A1 CA002307953A CA2307953A CA2307953A1 CA 2307953 A1 CA2307953 A1 CA 2307953A1 CA 002307953 A CA002307953 A CA 002307953A CA 2307953 A CA2307953 A CA 2307953A CA 2307953 A1 CA2307953 A1 CA 2307953A1
Authority
CA
Canada
Prior art keywords
human
dna
vegf145
recombinant
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002307953A
Other languages
English (en)
Inventor
Kenneth A. Thomas, Jr.
Richard L. Kendall
Andrew J. Bett
William R. Huckle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9724906.4A external-priority patent/GB9724906D0/en
Application filed by Individual filed Critical Individual
Publication of CA2307953A1 publication Critical patent/CA2307953A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés de thérapie génique destinés à favoriser l'angiogénèse dans un traitement des ischémies périphériques, cardiaques et d'autres tissus pathologiques à l'aide d'une molécule d'ADN (SEQ ID NO:1) qui code pour le VEGF¿145? humain formulé dans SEQ ID NO:2.
CA002307953A 1997-10-27 1998-10-23 Therapie genique pour la stimulation de l'angiogenese Abandoned CA2307953A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6362997P 1997-10-27 1997-10-27
US60/063,629 1997-10-27
GB9724906.4 1997-11-26
GBGB9724906.4A GB9724906D0 (en) 1997-11-26 1997-11-26 Gene therapy for stimulation of angiogenesis
PCT/US1998/022668 WO1999021590A1 (fr) 1997-10-27 1998-10-23 Therapie genique pour la stimulation de l'angiogenese

Publications (1)

Publication Number Publication Date
CA2307953A1 true CA2307953A1 (fr) 1999-05-06

Family

ID=26312655

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002307953A Abandoned CA2307953A1 (fr) 1997-10-27 1998-10-23 Therapie genique pour la stimulation de l'angiogenese

Country Status (5)

Country Link
EP (1) EP1027075A1 (fr)
JP (1) JP2001520875A (fr)
AU (1) AU751572B2 (fr)
CA (1) CA2307953A1 (fr)
WO (1) WO1999021590A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
CN1267550C (zh) 1994-03-08 2006-08-02 人体基因组科学有限公司 血管内皮生长因子2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
CA2348835A1 (fr) 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methodes de regulation de l'angiogenese et de l'integrite vasculaire a l'aide de ligands des recepteurs trk
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
CA2348906A1 (fr) 1999-09-21 2001-03-29 Ryuichi Morishita Therapie genique pour troubles cerebro-vasculaires
KR20020059609A (ko) 2000-08-04 2002-07-13 벤슨 로버트 에이치. 혈관 내피 성장 인자 ２
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
KR20030093316A (ko) 2001-04-13 2003-12-06 휴먼 게놈 사이언시즈, 인코포레이티드 혈관 내피 성장 인자 ２

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565225A (en) * 1896-08-04 Weighing-machine
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery

Also Published As

Publication number Publication date
WO1999021590A1 (fr) 1999-05-06
AU751572B2 (en) 2002-08-22
EP1027075A1 (fr) 2000-08-16
JP2001520875A (ja) 2001-11-06
AU1365299A (en) 1999-05-17

Similar Documents

Publication Publication Date Title
US7736655B2 (en) Soluble inhibitors of vascular endothelial growth factor and use thereof
AU738806B2 (en) Gene therapy for inhibition of angiogenesis
US7414027B2 (en) Peptide antagonists of vascular endothelial growth factor
NZ500530A (en) Truncated VEGF-B, VEGF-C, VEGF-3, PlGF, VRF-2, poxvirus ORF-1 and ORF-2 proteins
CA2307953A1 (fr) Therapie genique pour la stimulation de l'angiogenese
WO1999029861A1 (fr) Peptides antagonistes du facteur de croissance de l'endothelium vasculaire
US6793918B2 (en) In vivo stimulation of angiogenic activity
US6335010B1 (en) Gene therapy in coronary angioplasty and bypass
AU2001280841A1 (en) Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B
CA2483431A1 (fr) Molecules d'acides nucleiques a epissage alternatif
US20020065240A1 (en) Gene therapy for stimulation of angiogenesis
JP2002325590A (ja) ケラチノサイト増殖因子−２

Legal Events

Date Code Title Description
FZDE Dead